Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Enrique C. Morales-Villegas"'
Autor:
José L. Arenas-León, Enrique C. Morales-Villegas, Ernesto G. Cardona-Muñoz, Marco A. Alcocer-Gamba, Juan P. Ramirez-Contreras, Aleida Y. Contreras-Sandoval, Guillermo González-Galvez
Publikováno v:
Diabetology & Metabolic Syndrome, Vol 15, Iss 1, Pp 1-12 (2023)
Abstract Background To estimate the contemporary prevalence of established cardiovascular disease (CVD) in adults with type 2 diabetes (T2D) in Mexico. Methods CAPTURE was a multinational, non-interventional, cross-sectional study across 13 countries
Externí odkaz:
https://doaj.org/article/1d8f3541084b404b9f85acf8e3980995
Autor:
Manuel Odín De los Ríos-Ibarra, José Luis Leiva-Pons, Humberto Rodríguez-Reyes, Marco Antonio Alcocer-Gamba, Jorge Cortés-Lawrenz, Frida María Vizcaíno-Rios, Jaime Barragán-Luna, Julio Iván Farjat-Ruiz, Luis R. Virgen-Carrillo, Francisco Padilla-Padilla, Abel Pavia-López, Enrique C. Morales-Villegas, Natalie C. Ward, Leslie Marisol Lugo-Gavidia
Publikováno v:
Atherosclerosis Plus, Vol 50, Iss , Pp 32-39 (2022)
Background and aims: Dyslipidaemia is a significant risk factor for cardiovascular disease in the Mexican population. This analysis aimed to describe the baseline LDL-c levels of patients presenting to cardiovascular clinics and evaluate the proporti
Externí odkaz:
https://doaj.org/article/b731c2a132114e11a0c81da96326cb74
Publikováno v:
Archivos de Cardiología de México, Vol 93, Iss 1 (2023)
La hipertensión y la dislipidemia -especialmente la hipercolesterolemia- son factores de riesgo cardiovascular que impactan directamente en la prevalencia e incidencia de enfermedades cardiovasculares en todo el mundo y México no es la excepción.
Externí odkaz:
https://doaj.org/article/aced0d8f4fcb45978f8172f802d92d2d
Publikováno v:
International Journal of Hypertension, Vol 2011 (2011)
Reduction of LDL-cholesterol concentration in serum, blocking the isoprenylation of GTPases and the activation of myocyte-protective enzyme systems are three mechanisms that currently explain the lipid and non-lipid effects of statins. However, the d
Externí odkaz:
https://doaj.org/article/ba842b73da974499ad6ece4f9e3f2eab
Publikováno v:
Cardiovascular and Metabolic Science. 32:212-216
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::10546891e387ac61118ba1c10098659b
https://doi.org/10.35366/100800
https://doi.org/10.35366/100800
Publikováno v:
Archivos de cardiologia de Mexico.
Hypertension and dyslipidemia are key risk factors for cardiovascular disorders and mortality worldwide. To understand the local health system challenges faced in the management of the two conditions, a semi-systematic approach was adopted for quanti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e3500451135e4e65da09849b362d288c
https://pubmed.ncbi.nlm.nih.gov/35359036
https://pubmed.ncbi.nlm.nih.gov/35359036
Autor:
Vanita R. Aroda, Lars Bardtrum, Enrique C. Morales-Villegas, Julio Rosenstock, Anne Moeller Nielsen, Klaus Kallenbach, Melanie J. Davies
Publikováno v:
Diabetes. 70
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::223a970204605fa8f18c808dce305d5b
https://doi.org/10.2337/db21-663-p
https://doi.org/10.2337/db21-663-p
Autor:
Vanita R. Aroda, Martin Haluzik, Enrique C. Morales Villegas, Yasuo Terauchi, Erik Christiansen, Julio Rosenstock, Christin L. Hertz, Nebojsa Lalic, Ole K. Jeppesen, Yuksel Altuntas
Publikováno v:
Diabetes Care. 42:1724-1732
OBJECTIVE This trial compared the efficacy and safety of the first oral glucagon-like peptide 1 (GLP-1) receptor agonist, oral semaglutide, as monotherapy with placebo in patients with type 2 diabetes managed by diet and exercise alone. Two estimands
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfb2b4a23298148325b29391c8b58bd6
https://doi.org/10.2337/dc19-0749
https://doi.org/10.2337/dc19-0749
Physiologically, in the presence of an intracellular deficit of cholesterol, the LDLR synthesis, expression and function increase, thus uptaking and providing cholesterol to the cell. This process is counter-regulated by PCSK9 expression, the proteas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::22bf56f012d4d609d1680e2951ff0d1b
https://doi.org/10.2174/9781681083995118040007
https://doi.org/10.2174/9781681083995118040007
Autor:
Juan Urquiaga Calderón, Cesar Larrauri-Vigna, Enrique C Morales-Villegas, Alfonso Bryce Moncloa
Publikováno v:
Anales de la Facultad de Medicina, Vol 75, Iss 4, Pp 367-374 (2014)
La enfermedad ateroesclerótica comienza a temprana edad. La presencia de factores de riesgo, como la hipertensión arterial, tabaquismo, dislipidemia y diabetes mellitus, a lo que hoy se suman la obesidad y el síndrome metabólico, originan desde e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11bfe3808a6967706eff1e0492c94d9e
http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S1025-55832014000400014&lng=en&tlng=en
http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S1025-55832014000400014&lng=en&tlng=en